LuciAda 200 MG (Adagrasib)

Description

Adagrasib

Each film-coated tablet contains: Adagrasib. … 200 mg

INDICATION

LuciAda is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic non -small cell lung cancer (NSCLC), as determined by an FDA – approved test, who have received at least one prior systemic therapy.

DOSAGE AND USE

• Recommended dosage: 600 mg orally twice daily. • Swallow tablets whole with or without food.

STORAGE

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY

LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING

Keep medicine out of reach of Children. Do not administer LuciAda during Pregnancy and Lactation.